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Introduction
In the last 70 years, from 1952 to 2020, the clinical spectrum 
of renal cell carcinomas (RCC) has expanded by the 
increased recognition of new entities and the refinements of 
existing categories (1,2). The classification system has grown 
along with electron microscopy, immunohistochemistry, 
cytogenetics, and molecular diagnostic techniques. Some 
tumors such as ALK rearrangement-associated RCC, MiT 
family translocation renal carcinomas, SDH-deficient 
renal cancer or FH-deficient RCC, are defined by their 
molecular characteristics (3). The most recent World Health 
Organization (WHO) classification of renal neoplasms 
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account for more than 50 entities and provisional entities 
(4,5). New entities might be included in the upcoming 
WHO classification.
However, besides an increasing understanding of the 
tumor histologies and biological behaviour, only few tumor 
entities have a specific treatment and ongoing clinical trial 
are still adopting the old classification of clear cells RCC 
(ccRCC) and non-clear cells RCC (nccRCC) as selection 
criteria (6). 
This review will summarise and discuss the newly 
acquired data and evidence on the clinical, pathological, 
molecular features of the new entities included in the WHO 
2016 classification and of the emerging/provision entities, 
which will hopefully increase the awareness and their 
acceptance among clinicians and improve prognostication 
for individual patients. A PubMed search using the 
keywords “renal cell carcinoma”, “emerging entities”, 
“provisional entities”, “molecular classification”, from 2005 
and June 2020 was performed.
 It is beyond the scope of this review to describe in 
detail the various diagnostic pathological features and 
immunohistochemical antibody expression of these tumors. 
Detailed information about each entities are available in 
all the cited papers. We present the following article in 
accordance with the NARRATIVE REVIEW reporting 
checklist (available at http://dx.doi.org/10.21037/tau-20-
1150).
Narrative review
New renal tumor entities
Newly recognized epithelial renal tumours in the 2016 
WHO classification are HLRCC associated RCC, SDH-
deficient RCC, tubulocystic RCC, acquired cystic RCC, 
and clear cell papillary RCC (4).
Hereditary leiomyomatosis and renal cell carcinoma 
(HLRCC) syndrome-associated renal cell carcinoma/
FH-deficient RCC
HLRCC associated RCC are highly aggressive tumors 
that early metastasize, with frequent spread to regional 
lymph nodes, even if of small size (7,8). These rare tumors 
occur in people affected by an autosomal dominant 
tumor syndrome associated with germline mutations in 
the fumarate hydratase (FH) gene at chromosome 1q42. 
Patients with HLRCC syndrome usually present cutaneous 
leiomyomas and in female uterine leiomyoma and less 
frequently leiomyosarcomas (9,10). Thirty percent of the 
patients can also develop RCC, characterized by type 2 
papillary growth pattern and large nucleus with prominent 
orangiophilic or eosinophilic nucleolus, surrounded by a 
clear halo, resembling a viral inclusion which is the hallmark 
of these neoplasms. Same cytological features have been 
also described in uterine leiomyoma of these syndromic 
patients (11). An accurate diagnosis of these tumors is of 
primary importance for the correct management of the 
patients and their families. The germline mutations of 
the FH gene is the specific genetic alteration for these 
tumors and is detectable by IHC for FH antibody (loss of 
expression) or for S-2(2-succino)-cysteine (2SC) (strong 
and diffuse nuclear and cytoplasmic stain) or by molecular 
testing (12). In the setting of uncertain clinical and family 
history and unknown genetic status, is recommended to use 
“FH-deficient RCC” for tumors that show IHC-negative 
staining for FH and strong 2SC reactivity (12) (Figure 1A 
and 1B). Report of two syndromic cases treated in first-line 
with bevacizumab/erlotinib showed significant and long 
lasting response (13). 
Succinate dehydrogenase deficient neoplasia
These category of tumors account for about 0.05% to 
0.2% of renal neoplasms and are defined by the double-
hit inactivation of one of the SDH genes (SDHA, 
SDHB, SDHC, SDHD, and SDHAF2), an event that 
occurs only rarely in the absence of a germline mutation 
(14,15). Patients with germline mutation can also develop 
pheochromocytomas/paragangliomas, gastrointestinal 
stromal tumors, and pituitary adenomas. Presence of these 
rare type of tumors in the same patient/family should raise 
the suspicion of a germline mutation and encourage genetic 
counselling. The majority of the cases have loss of SDHB 
gene identifiable by loss of immunohistochemical stain. 
The median age at presentation is around 40 years with a 
wide range (14−76 years), they are typically solitary masses, 
multifocal and bilateral in 30% of patients. Low grade 
SDH-deficient RCC and without coagulative necrosis are 
associated with good outcome, while presence of necrosis, 
high grade and sarcomatoid features can present metastatic 
spread in 70% of the cases (16-18) (Figure 1C).
Tubulocystic RCC
Tubulocystic renal cell carcinoma (TCC RCC) was first 
comprehensively described by George Farrow and then by 
Amin et al. under the spectrum of collecting duct carcinoma. 
Because these tumors were entirely composed of tubules and 
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duct-like structures, it was initially call low-grade collecting 
duct carcinoma for its appearance and its significantly 
different behavior compared to the classical highly aggressive 
collecting duct carcinomas. Genetic alteration of TCC RCC 
are distinct from those of ccRCC, pRCC, ChRCC and 
also from collecting duct carcinomas. More than 80 cases 
have been reported so far with strong prevalence in males 
(male/female ratio of 7:1) and higher incidence in the fifth 
and sixth decade. Most of the tumors are cystic and in pT1 
stage and behave in an indolent fashion. Only rare cases 
presented metastasis to the pelvic lymph nodes, bone, liver 
and peritoneum (19-23) (Figure 1D).
Clear cell papillary RCC
Clear cell Papillary RCC (CCPRCC) is thought to have a 
prevalence rate of approximately 1–4% and that about 6% of 
low-grade ccRCC are, in fact, CCPRCC, making this entity 
the fourth most common RCC subtype. The characteristic 
immunoprofile with diffuse cytokeratin 7 staining, GATA3 
positivity, “cup-shaped” carbonic anhydrase IX staining 
distribution, and negative results for AMACR and CD10, 
along with the absence of VHL alterations in almost all 
tumor, distinguish this entity from ccRCC and papillary 
RCC. When the immunohistochemistry shows an 
imperfect staining pattern, current recommendations advise 
to classify such tumors as ccRCC and to refers to genetic 
analysis for VHL mutation or chromosome 3p loss (24-26) 
(Figure 2A,B,C).
Acquired cystic disease-associated renal cell carcinoma 
(ACD-RCC)
Patients with acquired cystic disease (ACD) of the kidney 
have a risk of develop a renal tumors about 100 times higher 
than the general population, a risk that increases with the 
duration of the dialysis. ACD-RCC is specific for the cystic 
disease condition and occurs only in end-stage renal disease 
patients, but patients with ACD can develop also other 
RCC histotypes. The vast majority of ACD-RCC present 
intratumoral calcium oxalate deposition in the luminal 
structures and in the stroma. These tumors have been 
usually detected at an early stage, thus the clinical course is 
usually indolent. Few cases with sarcomatoid component 
have been reported and were associated with poor outcome 
(27-30) (Figure 2D).
Emerging or provisional renal tumour entities
The 2016 WHO classification includes some rare entities, 
not yet well characterized in terms of morphology, 
immunohistochemical stain and genetic features, therefore 
Figure 1 FH-Deficient RCC, at low (2×) (A) and high magnification (20×) (B), with strong and diffuse positivity for 2SC and loss of FH 
expression (inserts); Succinate Dehydrogenase Deficient Neoplasia (10×) (C) with loss of SDH2 expression (insert); Tubulo-cystic RCC (10×)
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placed under the category “emerging/provisional 
tumors”. These entities are thyroid-like follicular RCC, 
RCCs associated with ALK gene rearrangement, Renal 
cell carcinoma with (angio) leiomyomatous stroma and 
TCEB1 mutated RCC. RCC in neuroblastoma survivors 
was removed from 2016 WHO classification and its now 
considered an emerging entity.
Thyroid like follicular RCC
To data, less than 40 cases of Thyroid like follicular RCC 
have been reported, 27 in female and 12 in male patients 
and a median age of 35 years. These curious entities are 
characterized by structures resembling thyroid follicles with 
accumulation of inspissated colloid-like material that closely 
mimic a well-differentiated thyroid follicular neoplasms. The 
main differential diagnosis are a chronic pyelonephritis or a 
metastatic thyroid carcinoma. Thyroid like follicular RCC are 
in most of the cases indolent neoplasms. Few cases reported 
spread in hilar lymph nodes and distant metastasis, but all the 
patients survived after surgical resection (31-34) (Figure 2E).
Anaplastic lymphoma kinase (ALK) Rearrangement-
Associated RCC (ALK-RCC) 
ALK-RCC has been described in 2011 and less than 30 
cases have been reported so far (35-43). 
They are usually solitary tumor, not associated with any 
syndrome, with a slight prevalence in males and reported 
in a wide age range, including adolescents. Thirty% of the 
cases demonstrated malignant behavior with metastasis 
and death. Variable and multiple morphologies can be 
seen in this type of tumor and the definitive diagnosis can 
only be done by performing IHC for ALK antibody and 
FISH analysis for ALK rearrangement (44) (Figure 3A,B). 
Multiple ALK fusion gene partners have been identified. 
Mucinous background, intracytoplasmic mucin and myxoid 
changes have been reported in a subsets of cases and can 
be a helpful clue to recognize these rare tumor eligible for 
a potential targetable therapy. “ALK IHC screening for 
unclassifiable RCCs with heterogeneous features” has been 
proposed by Kuroda and colleagues (43).
Target therapy against ALK activation (i.e., ALK 
inhibitors alectinib and crizotinib) have been developed 
for ALK rearranged tumors and have proven efficacy and 
tolerability. Short term clinical and radiographic response 
to alectinib has been recently reported in 3 patients with 
metastatic EML4-ALK rearranged tumors (45). In children 
and adolescents ALK-RCC resembles renal medullary 
carcinoma and collecting duct carcinoma, are frequently 
Figure 2 Clear cell papillary RCC. Clear cells of low nuclear grade, variable papillary, tubular-acinar and cystic architecture in a 
fibroleiomyomatous stroma (10×) (A), “cup-shaped” carbonic anhydrase IX staining distribution (20×) (B), strong and diffuse CK7 positivity 
(20×) (C). Acquired cystic disease-associated renal cell carcinoma (4×) (D), note the oxalate crystals (arrow) at higher magnification (insert); 
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located in the medulla or renal pelvis and harbor VCL-
ALK and TPM3-ALK fusion. Until recently, VCL-
ALK rearrangements has been reported only in pediatric 
patients of African American origin with the sickle-cell 
trait. Some cases in adult patients have been described as 
metanephric adenoma, mucinous tubular and spindle cell 
carcinoma, MiTF RCC (due to the positivity for TFE3 by 
IHC without FISH confirmed rearrangement for Xp11.2 
translocation) (46,47). 
The differential diagnosis in these cases is of great 
importance due to the differences in prognosis compared 
to a benign and indolent entities and to the implication in 
therapeutic choice for ALK rearranged tumors.
Renal cell carcinoma with (angio) leiomyomatous 
stroma (RCCLMS)
Multiple names have been used to describe this rare 
entity: mixed renal tumour with carcinomatous and 
fibroleiomyomatous components, RCC associated with 
prominent angioleiomyoma-like proliferation, clear cell 
RCC with smooth muscle stroma, RCC with clear cells, 
smooth muscle stroma and negativity for 3p deletion, 
RCC with leiomyomatous stroma, and RCC with 
angioleiomyomatous-like stroma. These rare tumors are 
constituted by two admixed components, epithelial—usually 
nest/tubules/papillary structure of clear cell, with low grade 
nuclei—and stromal—non-neoplastic leiomyomatous or 
fibroleiomyomatous (48-52).
The presence of a prominent leiomyomatous stroma 
is not a feature of a specific entity, but can be seen in 
otherwise typical ccRCC and even in papillary RCC.
According to recent publication by Shah and colleagues, 
the morphology, immunohistochemical features, and 
molecular alterations of RCCLMS distinguish this 
entity from CCRCC and CCPRCC. Of the 18 sporadic 
RCCLMS they included in their analysis, 4 harbour 
TSC1, 4 TSC2, 6 MTOR, and/or 2 TCEB1 mutations 
and all have an intact VHL gene. Their findings support 
the suggestion that these tumors represent the sporadic 
counterpart to morphologically identical tumors occurring 
in TSC patients (53).
TCEB1 Renal cell carcinoma
A small fraction of wt-VHL RCC are characterized by 
inactivation of the TCEB1 gene that encodes for a protein 
part of the E3 ubiquitin ligase complex. Inactivation of 
TCEB1 increases HIF stabilisation via the same mechanism 
as VHL inactivation. These tumors are often accompanied 
by loss of chromosome 8 (often in the form of monosomy). 
These new entity resembles ccRCC, express CAIX as well, 
and usually present thick fibromuscular bands transecting 
the tumor and clear cell cytology with voluminous 
Figure 3 ALK Rearrangement-associated RCC (A, 10×) with mucinous background, ALK-IHC membrane expression (B, 10×); HOT (C, 
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cytoplasm. Although initial data on this subset suggested 
that they are nonaggressive, recent reports of aggressive 
behaviour have been published (53-56).
New aspects in classic tumor entities
Clear cell RCC: VHL alterated and VHL wild type 
entities
Clear cell RCC is the most prevalent histotype among 
RCC, accounting for about 70% of all cases, historically 
defined by clear cell cytoplasm and a characteristic network 
of small, thin walled, vasculature. The majority of ccRCC 
are characterized by the biallelic loss of the VHL tumor 
suppressor gene in the short arm of chromosome 3 that 
can occurs via mutations, copy deletion and promoter 
hypermethylation. Patients affected by von Hippel–
Lindau syndrome inherited a single inactivated copy of 
the VHL gene and usually develop other tumor types such 
as hemangioblastomas, pheochromocytoma, pancreatic 
cysts, endolymphatic sac tumor, and cystadenomas of the 
epididymis (men) or broad ligament of the uterus (women) 
(57-59). In the last decades, some tumor entities have 
been described with clear cell cytoplasm and showing 
morphological overlap with clear cell papillary RCC, 
RCC with (angio) leiomyomatous stroma, translocation 
carcinomas, and TCEB1 renal cancer. However, these 
tumors do not share the same genetic aberrations of 
ccRCC and should be distinguished from the classical 
VHL-mutated ccRCC (56). A correct classification of 
these tumors is relevant from a clinical prognostic point of 
view since these tumors (i.e., CCPRCC, RCCLMS, MiT 
family translocation RCC) are mostly indolent while others 
such as ccRCC VHL-wild type have been associated with 
a higher aggressiveness, sarcomatoid features and rapid 
progression (60-62).
Papillary renal cell carcinoma: more than just type 1 
and type 2
Papillary RCC has seen the most marked changes during 
the last decade. It is a heterogeneous category that 
comprehends indolent entities and aggressive high lethal 
tumors. The molecular characterization published in 2016 
distinguished two categories: type 1, the most uniform 
subgroup, typically associated with MET alterations, and 
type 2 tumors characterized by different genetic alterations 
(such as CDKN2A silencing, SETD2 mutations, TFE3 
fusions, and increased expression of the NRF2-antioxidant 
response element pathway) and composed by multiple 
specific neoplasms rather than a single specific entity. 
A CpG island methylator phenotype (CIMP) has been 
reported in a FH deficient pRCC (often associated with 
the hereditary leiomyomatosis and renal cell carcinoma 
syndrome [HLRCC]) (63). Type 2 papillary RCC had worse 
outcomes compared to type 1, and usually have higher 
nuclear grade, higher stage and tumor size with a 6% of 
lymph nodes metastasis (64).
Chromophobe RCC: How to distinguish the good one 
from the bad one
Chromophobe RCC (ChRCC) accounts for approximately 
5-7% of all adult renal tumors and it is usually composed 
of epithelial cells, polygonal pale cells, and eosinophilic 
cells, with accentuated cellular membranes, raisin-like 
nuclei and perinuclear halos. Due to constitutive atypia of 
the nuclei, the presence of binucleation, and the nucleolar 
prominence, the World Health Organization/International 
Society of Urologic Pathologists (WHO/ISUP) nucleolar 
system cannot be applied in ChRCC (4). However, a 
histological grading system with a prognostic validation 
is greatly needed. Its course is generally indolent but a 
minority of cases develop metastases and respond poorly 
to the currently available therapy. Grading system proposal 
are based on the presence of three parameters: sarcomatoid 
differentiation, histological coagulative tumor necrosis, and 
presence of mitosis (65-68).
Using such a grading system, a statistically significant 
difference was reported in overall survival in univariate 
analysis. However, low to medium concordance was 
reported in the identification of mitosis. Therefore, a two-
tiered tumor grading system based only on presence of 
sarcomatoid differentiation and necrosis was proposed 
by Ohashi et al. This system showed high accuracy in 
prediction of time to progression, overall survival and high 
interobserver reproducibility (67,68).
From a molecular prospective, ChRCC is characterized 
by mult iple  chromosome losses  (chromosome Y, 
1,2,6,10,13,17.21), a reduced expression of “Copy-
number alterations Yielding Cancer Liabilities Owing to 
Partial losS” (CYCLOPS) genes and TP53 and PTEN 
mutations (69). Patients with metastatic disease has an 
increased tumor mutation rates in these two genes and an 
imbalanced chromosome duplication (70). In difficult cases, 
chromosomal copy number alterations can be used for the 
differential diagnosis between the eosinophilic variant of 
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ChRCC and oncocytoma. Losses of chromosome 1 and 
Y has been found also in benign oncocytoma while losses 
of chromosomes 2, 6, 10, or 17 are not and can be used to 
exclude the benign entity (71-74). Recently the group of 
Ohashi et al. discovered that a reduced CDKN1A mRNA 
expression levels and CDKN1A immuno-negativity were 
associated with poor outcome in ChRCC (75).
In case of hybrid tumors and in patients with multiple 
oncocytic tumors, the analysis of FLCN gene (folliculin) 
can be performed to support the diagnosis of Birt-Hogg-
Dubè syndrome (44).
High-grade oncocytic tumor (HOT) and Low-grade 
oncocytic tumor (LOT)
In the spectrum of oncocytic tumors difficult to classify, two 
distinct entities have been recently proposed: High-grade 
oncocytic tumor (HOT) and Low-grade oncocytic tumor 
(LOT). HOT and LOT are eosinophilic tumors that do not 
fit in any of the currently recognized tumor categories, in 
particular oncocytic tumors such as oncocytoma, ChRCC, 
hybrid oncocytic tumors either sporadic or syndromic. 
Twenty-two HOT cases have been published since now, one 
sporadic and just one in a patient with TSC (76-80). The 
cases reported are more often females with a median age 
of 55 years, all with indolent behavior. The immunoprofile 
(CD117+, CK7 focal) and the electronic microscopy 
appearance mimics the one of the oncocytoma, however 
the high-grade morphology, with enlarged nucleoli that 
resemble viral inclusions, and the cytoplasmic vacuoles are 
not usually encountered in a classical oncocytoma. FLCN 
mutation detection can be of help in distinguishing a hybrid 
tumor from a HOT.
On the other hand, LOT presents diffuse positivity for 
CK7, invariably CD117-negative and has been described 
as eosinophilic ChRCC with absence of any consistent 
chromosomal losses or gains. The cells have a low-grade 
appearance with often delicate perinuclear clearing. The 
28 cases published consisted in single small tumors with 
indolent course, slightly prevalent in females with a median 
age of 66 years (81-83) (Figure 3C and 3D).
MiT family translocation RCC (tRCC)
tRCC accounts for 1-4% of RCC in adult and around 
50% of pediatric RCC. They are characterised by gene 
fusions involving TFE3 or TFEB, 2 members of the 
MiT family of transcription factors. The most common 
chromosomal translocations are Xp11, involving the 
oncogenic activation of the TFE3 transcription factor 
(Figure 4A) and, less frequently, 6;11 (p21;q12), involving 
TFEB. Xp11 translocation RCCs typically have a papillary/
nested growth pattern and are composed of clear cells with 
frequent associated psammomatous calcifications whereas 
6;11 translocations RCC have usually nested architecture 
and are constituted of a biphasic population of larger and 
smaller epithelioid cells clustered around hyaline basement 
membrane material. t(6;11) RCCs are usually indolent 
(84-86). Among this category, Gupta et al. identified 25 cases 
of TFEB-amplified RCC associated with amplifications 
of VEGFA (which exists in 6p21, same with TFEB) that 
showed oncocytic and tubulopapillary features with high-
grade nuclei, and their clinical courses were aggressive 
with metastasis and death from RCC in 46% of cases (87). 
To date, 54 cases of TFEB-amplified tumors have been 
reported, a small percentage of which harboring both TFEB 
translocation and amplification. Overall, TFEB amplified 
tumors shows high nuclear grade, pseudopapillary/nested/
tubular structure and an aggressive clinical behaviour. 
Notably, 50% of the published cases were negative for 
TFEB expression by immunohistochemistry (88).
Mucinous tubular spindle cell carcinoma (MTSCC)
Already included as in the 2004 WHO under the 
name mucinous tubular and spindle cell carcinoma, 
these tumors often exhibits overlapping histologic and 
immunophenotypic feature with PRCC type 1. While 
the classic MTSCC harbors multiple chromosomal losses 
without the trisomy of chr 7 and 17, the overlapping 
cases show a chromosomal alteration pattern similar to 
solid variant of PRCC type 1 cases, including gains of 
chromosomes 7 and 17 (89,90). To distinguish these tumors 
with overlapping histology has been recently proposed 
a new cancer-specific and lineage-specific biomarkers 
VSTM2A specifically overexpressed in MTSCC (91).
MTSCC generally presents at low pathologic stage 
at the time of excision, and the majority of the MTSCC 
with classic histology behave in an indolent fashion. 
However, presence of high nuclear grade and sarcomatoid 
features have been associated with lethal outcomes (92,93) 
(Figure 4B).
Renal medullary carcinoma and Collecting duct 
carcinoma
Renal medullary carcinomas (RMCs) and collecting duct 
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carcinomas (CDCs) are well-know, rare high grade renal 
tumors, usually sited in the renal medullary region. They 
often present at high-stage and are associated with a dismal 
prognosis. On the basis of the recent modified diagnostic 
approach and new entities, 25% of tumors previously 
diagnosed as CDC were reclassified as FH-deficient 
RCC. Exclusion of metastatic adenocarcinoma, urothelial 
carcinoma of the pelvi-calyceal system, renal medullary 
carcinoma, and FH-deficient RCC are required to render a 
diagnosis of CDC. RMC typically in children or young adults 
of African, South American and Mediterranean origin with 
sickle cell trait or disease. The diagnostic criteria for RMC are 
stricter and include the presence of hemoglobinopathy (sickle 
cell trait or related hemoglobinopathies and/or finding sickle-
shaped erythrocytes (drepanocytes) in the histologic samples) 
and complete loss of SMARCB1 (INI1) expression by IHC 
(94-97) (Figure 4C and 4D).
Discussion: recommendations for the next WHO 
classification
Eosinophilic solid and cystic RCC (ESC RCC)
ESC RCC is an emerging renal tumor entity not yet part 
of the 2016 WHO classification of genitourinary tumors 
(4,98,99). It was recently described as a sporadic neoplasms 
occurring in young women, usually solitary, small and 
with indolent behavior. Subsequent studies have reported 
identical tumor also in males and multifocal, in a minority 
of cases. Metastases have been reported in four cases so far. 
Ten percent of the patients with tuberous sclerosis-complex 
(TSC) can present this type of tumor, firstly described with 
“granular eosinophilic-macrocystic morphology” by Guo 
et al. (100-102). In a case series of unclassified eosinophils 
tumor in patients of 35 years of age or younger, 30% of 
the cases were classified as ESC-RCC (17). Solid and cystic 
architecture, voluminous eosinophilic cytoplasm, granular 
cytoplasmic stippling, CK20 positivity either diffuse or focal 
are the typical features of these tumors, although CK 20 
negative cases (10-15%) have been reported (Figure 5A and 
5B). Next generation sequencing analysis and karyotype 
profiling evidenced that ESC-RCC are characterized by 
somatic tuberous sclerosis gene mutations (TSC1 and TSC2) 
in the great majority of cases and recurring chromosomal 
copy number gains and losses. Since many of the genes 
involved in these alterations are part of the regulation of 
MTOR signaling pathway, therapies targeting the mTOR 
pathway in these RCC can be considered (103,104).
Biphasic squamoid papillary RCC
Initially reported in 2012 by Petersson et al. and later in a 
Figure 4 Xp11 translocation RCCs (A, 10×), TFE3 IHC staining (insert); Mucinous tubular spindle cells carcinoma (B, 4×); Renal medullary 
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larger series by Hes et al. this new entity may represent a 
distinct subtype of papillary RCC type 1, on the basis of 
the morphological, immunohistochemical and molecular 
similarities (105,106).
The name is  given by the presence of two cell 
populations: one constituted by larger eosinophilic 
cells with abundant cytoplasm and higher-grade nuclei 
designated as ‘squamoid’ (squamous cell-like), organized 
in glomeruloid or micronodular formations resembling 
alveolar structures; and a population of smaller cells with 
amphophilic or clear and scant cytoplasm, admixed with 
the larger cells. These tumors can be multifocal, bilateral, 
associated with other tumors such as multiple papillary 
adenomas, papillary RCC, clear cell RCC, and low-grade 
urothelial carcinoma, and can express malignant behaviour 
with metastasis, recurrence, or death due to the disease in 
15% patients (107-110) (Figure 5C).
Papillary renal neoplasm with reverse polarity (PRNRP)
A distinct subset of papillary renal tumors with reverse 
polarity was recently described by Al-Obaidy and 
colleagues (111). These tumors are characterized by 
low-grade nuclear features, inverted nuclear location, 
eosinophilic cytoplasm, branching papillae with thin 
fibrovascular cores and indolent clinical behavior. They 
are characteristically positive for GATA3 and L1CAM 
and the great majority of them [93% in the series of 
Kim et al. (112)] harbors recurrent mutation of KRAS, 
whereas no KRAS mutation have been reported in any 
of papillary type 1 and type 2 cohort used as controls 
(112,113). After a median follow-up of 54 months, all 
patients with PRNRP were alive with no evidence of 
disease (Figure 5D) (Table 1).
Conclusions
In addition to common histological subtypes known for decades, 
many entities with distinct morphological and molecular 
features are under active investigation and may be included 
in future classifications. The more accurate identification of 
these tumors with the help of ancillary techniques and genetic 
analysis will improve patient’s stratification and therapy and 
may have an impact on their families in the specific case of a 
genetic syndrome-associated RCC. 
Figure 5 Eosinophilic solid and cystic RCC at low magnification (A, 2×) and high magnification (B, 20×), CK20 expression (insert); Biphasic 
squamoid papillary RCC (C, 10×), BCL1 IHC stained the squamoid cells (insert); Papillary renal neoplasm with reverse polarity (D, 40×), 
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